Next Article in Journal
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
Next Article in Special Issue
Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma
Previous Article in Journal
Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells
Previous Article in Special Issue
Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation
Case Report

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

1
Medical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, 65, 70124 Bari, Italy
2
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy
3
Pharmacogenetics and Molecular Diagnostic Unit, IRCCS IstitutoTumori “Giovanni Paolo II”, Viale Orazio Flacco, 65, 70124 Bari, Italy
4
Department of Radiology, IRCCS IstitutoTumori “Giovanni Paolo II”, VialeOrazio Flacco, 65, 70124 Bari, Italy
5
Histopathological Unit, IRCCS IstitutoTumori “Giovanni Paolo II”, VialeOrazio Flacco, 65, 70124 Bari, Italy
6
Medical ThoracicOncology Unit, IRCCS IstitutoTumori “Giovanni Paolo II”, VialeOrazio Flacco, 65, 70124 Bari, Italy
7
Dipartimento di Farmacia-Scienze del Farmaco, Universityof Bari, 70125 Bari, Italy
8
ScientificDirectorate, IRCCS IstitutoTumori “Giovanni Paolo II”, Viale OrazioFlacco, 65, 70124 Bari, Italy
*
Author to whom correspondence should be addressed.
Co-first authors.
Co-last authors.
Cancers 2019, 11(6), 749; https://doi.org/10.3390/cancers11060749
Received: 12 May 2019 / Revised: 21 May 2019 / Accepted: 28 May 2019 / Published: 29 May 2019
(This article belongs to the Special Issue Advances in Pancreatic Cancer Research)
The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. It is interesting to note that two neoplasms shared a common mutation ofthe B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival rate. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a leading justification of the long survival of the patient considered in this report. View Full-Text
Keywords: pancreatic ductal adenocarcinoma; non-small cell lung cancer; double primary cancers; B7-H3; gefitinib; chemotherapy pancreatic ductal adenocarcinoma; non-small cell lung cancer; double primary cancers; B7-H3; gefitinib; chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Brunetti, O.; Badalamenti, G.; De Summa, S.; Calabrese, A.; Argentiero, A.; Fucci, L.; Longo, V.; Galetta, D.; Perrotti, P.M.S.; Pinto, R.; Petriella, D.; Danza, K.; Tommasi, S.; Leonetti, F.; Silvestris, N. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers 2019, 11, 749. https://doi.org/10.3390/cancers11060749

AMA Style

Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers. 2019; 11(6):749. https://doi.org/10.3390/cancers11060749

Chicago/Turabian Style

Brunetti, Oronzo, Giuseppe Badalamenti, Simona De Summa, Angela Calabrese, Antonella Argentiero, Livia Fucci, Vito Longo, Domenico Galetta, Pia M.S. Perrotti, Rosamaria Pinto, Daniela Petriella, Katia Danza, Stefania Tommasi, Francesco Leonetti, and Nicola Silvestris. 2019. "Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy" Cancers 11, no. 6: 749. https://doi.org/10.3390/cancers11060749

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop